A peer-reviewed paper published in Nature Communications has reported that semaglutide slowed epigenetic ageing markers across several DNA methylation clocks. The findings come from a post hoc analysis of a 32-week randomised double-blind placebo-controlled phase 2b trial originally focused on HIV-associated lipohypertrophy.
The trial enrolled 84 participants. Of these, 45 received semaglutide and 39 received placebo. Blood samples allowed researchers to profile DNA methylation at the start and at week 32.
In adjusted analyses, semaglutide reduced epigenetic ageing compared with placebo. The reductions included PhenoAge by 4.9 years per year, PCGrimAge by 3.1, GrimAge V2 by 2.3, OMICmAge by 2.2, RetroAge by 2.2, and DunedinPACE by 0.09 units, equivalent to 9 percent slower pace.
Systems-based clocks showed parallel reductions in measures of inflammation, brain ageing, and heart ageing. These results provide the first randomised clinical trial evidence that semaglutide can modulate biological ageing as measured by epigenetic clocks.
The study underscores the value of rigorous, evidence-based medical research that places the human person at the centre of inquiry. Rather than rushing to policy prescriptions or broad access claims, such work builds objective understanding through careful methodology and transparent reporting of both strengths and weaknesses.
Limitations temper the excitement. The analysis was post hoc, the sample size modest at 84 participants, the cohort specific to people with HIV, and the follow-up limited to 32 weeks. These factors restrict how far the results can be generalised.
